Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Notes Payables (2017 - 2025)

vTv Therapeutics' Notes Payables history spans 10 years, with the latest figure at $328000.0 for Q3 2025.

  • For Q3 2025, Notes Payables changed N/A year-over-year to $328000.0; the TTM value through Sep 2025 reached $328000.0, changed N/A, while the annual FY2023 figure was $191000.0, 14.73% down from the prior year.
  • Notes Payables for Q3 2025 was $328000.0 at vTv Therapeutics, up from $191000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $636000.0 in Q3 2021 and bottomed at $191000.0 in Q4 2023.
  • The 4-year median for Notes Payables is $328000.0 (2025), against an average of $380714.3.
  • The largest YoY upside for Notes Payables was 204.76% in 2021 against a maximum downside of 73.15% in 2021.
  • A 4-year view of Notes Payables shows it stood at $256000.0 in 2021, then fell by 12.5% to $224000.0 in 2022, then decreased by 14.73% to $191000.0 in 2023, then skyrocketed by 71.73% to $328000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Notes Payables are $328000.0 (Q3 2025), $191000.0 (Q4 2023), and $473000.0 (Q3 2023).